{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T06:12:24Z","timestamp":1790921544152,"version":"4.1.0"},"reference-count":47,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal.chestnet.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["CHEST"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.chest.2025.12.035","type":"journal-article","created":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T07:23:09Z","timestamp":1768202589000},"page":"1476-1487","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Efficacy of Antiinflammatory Therapies for Adults With Non-Cystic Fibrosis Bronchiectasis"],"prefix":"10.1016","volume":"169","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3948-1601","authenticated-orcid":false,"given":"Shota","family":"Yamamoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Niitsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyoharu","family":"Fukushima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayako","family":"Shiozawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryosuke","family":"Imai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuki","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth N.","family":"Olivier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy R.","family":"Aksamit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kozo","family":"Morimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.chest.2025.12.035_bib1","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1183\/13993003.01033-2015","article-title":"Changes in the incidence, prevalence and mortality of bronchiectasis in the UK from 2004 to 2013: a population-based cohort study","volume":"47","author":"Quint","year":"2016","journal-title":"Eur Respir J"},{"issue":"176","key":"10.1016\/j.chest.2025.12.035_bib2","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0179-2024","article-title":"Neutrophilic inflammation in bronchiectasis","volume":"34","author":"Chalmers","year":"2025","journal-title":"Eur Respir Rev"},{"issue":"1","key":"10.1016\/j.chest.2025.12.035_bib3","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01050-2024","article-title":"Targeting neutrophil serine proteases in bronchiectasis","volume":"65","author":"Chalmers","year":"2025","journal-title":"Eur Respir J"},{"issue":"3","key":"10.1016\/j.chest.2025.12.035_bib4","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1164\/ajrccm.158.3.9710090","article-title":"Inhaled fluticasone reduces sputum inflammatory indices in severe bronchiectasis","volume":"158","author":"Tsang","year":"1998","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"10.1016\/j.chest.2025.12.035_bib5","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1136\/thx.2002.003236","article-title":"Inhaled fluticasone in bronchiectasis: a 12 month study","volume":"60","author":"Tsang","year":"2005","journal-title":"Thorax"},{"issue":"4","key":"10.1016\/j.chest.2025.12.035_bib6","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1007\/s11096-012-9659-6","article-title":"Budesonide efficacy and safety in patients with bronchiectasis not due to cystic fibrosis","volume":"34","author":"Hernando","year":"2012","journal-title":"Int J Clin Pharm"},{"issue":"6","key":"10.1016\/j.chest.2025.12.035_bib7","doi-asserted-by":"crossref","first-page":"2501126","DOI":"10.1183\/13993003.01126-2025","article-title":"European Respiratory Society clinical practice guideline for the management of adult bronchiectasis","volume":"66","author":"Chalmers","year":"2025","journal-title":"Eur Respir J"},{"issue":"suppl 1","key":"10.1016\/j.chest.2025.12.035_bib8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/thoraxjnl-2018-212463","article-title":"British Thoracic Society Guideline for bronchiectasis in adults","volume":"74","author":"Hill","year":"2019","journal-title":"Thorax"},{"issue":"9842","key":"10.1016\/j.chest.2025.12.035_bib9","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/S0140-6736(12)60953-2","article-title":"Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial","volume":"380","author":"Wong","year":"2012","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.chest.2025.12.035_bib10","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1001\/jama.2013.2290","article-title":"Effect of long-term, low-dose erythromycin on pulmonary exacerbations among patients with non-cystic fibrosis bronchiectasis: the BLESS randomized controlled trial","volume":"309","author":"Serisier","year":"2013","journal-title":"JAMA"},{"issue":"12","key":"10.1016\/j.chest.2025.12.035_bib11","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1001\/jama.2013.1937","article-title":"Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis: the BAT randomized controlled trial","volume":"309","author":"Altenburg","year":"2013","journal-title":"JAMA"},{"issue":"10","key":"10.1016\/j.chest.2025.12.035_bib12","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/S2213-2600(19)30191-2","article-title":"Long-term macrolide antibiotics for the treatment of bronchiectasis in adults: an individual participant data meta-analysis","volume":"7","author":"Chalmers","year":"2019","journal-title":"Lancet Respir Med"},{"issue":"4","key":"10.1016\/j.chest.2025.12.035_bib13","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1183\/13993003.00148-2015","article-title":"A randomised, placebo-controlled study of the CXCR2 antagonist AZD5069 in bronchiectasis","volume":"46","author":"De Soyza","year":"2015","journal-title":"Eur Respir J"},{"issue":"1","key":"10.1016\/j.chest.2025.12.035_bib14","doi-asserted-by":"crossref","first-page":"67","DOI":"10.4046\/trd.2021.0051","article-title":"Efficacy of roflumilast in bronchiectasis patients with frequent exacerbations: a double-blinded, randomized, placebo-controlled pilot clinical trial","volume":"85","author":"Juthong","year":"2022","journal-title":"Tuberc Respir Dis"},{"issue":"6","key":"10.1016\/j.chest.2025.12.035_bib15","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/S2213-2600(14)70050-5","article-title":"Atorvastatin as a stable treatment in bronchiectasis: a randomised controlled trial","volume":"2","author":"Mandal","year":"2014","journal-title":"Lancet Respir Med"},{"issue":"2","key":"10.1016\/j.chest.2025.12.035_bib16","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.chest.2017.05.017","article-title":"A randomized controlled trial of atorvastatin in patients with bronchiectasis infected with Pseudomonas aeruginosa: a proof of concept study","volume":"152","author":"Bedi","year":"2017","journal-title":"Chest"},{"issue":"22","key":"10.1016\/j.chest.2025.12.035_bib17","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1056\/NEJMoa2021713","article-title":"Phase 2 trial of the DPP-1 inhibitor brensocatib in bronchiectasis","volume":"383","author":"Chalmers","year":"2020","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.chest.2025.12.035_bib18","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1056\/NEJMoa2411664","article-title":"Phase 3 trial of the DPP-1 inhibitor brensocatib in bronchiectasis","volume":"392","author":"Chalmers","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.chest.2025.12.035_bib20","unstructured":"Higgins JTP, Thomas J, Chandler J, et al, eds. Cochrane Handbook for Systematic Reviews of Interventions, version 6.5. Cochrane; 2024. Updated August 2024. Accessed March 8, 2026. https:\/\/www.cochrane.org\/handbook"},{"issue":"11","key":"10.1016\/j.chest.2025.12.035_bib21","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann Intern Med"},{"issue":"2","key":"10.1016\/j.chest.2025.12.035_bib22","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jclinepi.2012.08.001","article-title":"GRADE guidelines: 13. Preparing summary of findings tables and evidence profiles-continuous outcomes","volume":"66","author":"Guyatt","year":"2013","journal-title":"J Clin Epidemiol"},{"issue":"12","key":"10.1016\/j.chest.2025.12.035_bib23","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1016\/j.jclinepi.2011.01.011","article-title":"GRADE guidelines: 5. Rating the quality of evidence--publication bias","volume":"64","author":"Guyatt","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.chest.2025.12.035_bib24","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.chest.2025.12.035_bib25","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2022-074495","article-title":"A guide and pragmatic considerations for applying GRADE to network meta-analysis","volume":"381","author":"Izcovich","year":"2023","journal-title":"BMJ"},{"issue":"32","key":"10.1016\/j.chest.2025.12.035_bib26","doi-asserted-by":"crossref","first-page":"E901","DOI":"10.1503\/cmaj.200077","article-title":"Development of the Instrument to assess the Credibility of Effect Modification Analyses (ICEMAN) in randomized controlled trials and meta-analyses","volume":"192","author":"Schandelmaier","year":"2020","journal-title":"CMAJ"},{"issue":"1","key":"10.1016\/j.chest.2025.12.035_bib27","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/s12931-023-02444-z","article-title":"Dipeptidyl peptidase-1 inhibition with brensocatib reduces the activity of all major neutrophil serine proteases in patients with bronchiectasis: results from the WILLOW trial","volume":"24","author":"Cipolla","year":"2023","journal-title":"Respir Res"},{"issue":"5","key":"10.1016\/j.chest.2025.12.035_bib28","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1164\/rccm.202408-1545OC","article-title":"Broad immunomodulatory effects of the dipeptidyl-peptidase-1 inhibitor brensocatib in bronchiectasis: data from the phase 2, double-blind, placebo-controlled WILLOW trial","volume":"211","author":"Johnson","year":"2025","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.chest.2025.12.035_bib29","doi-asserted-by":"crossref","DOI":"10.1164\/ajrccm.2025.211.Abstracts.A3495","article-title":"Efficacy of brensocatib in patients with non-cystic fibrosis bronchiectasis with vs without maintenance use of macrolides: an analysis of the ASPEN trial","volume":"211","author":"Haworth","year":"2025","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.chest.2025.12.035_bib30","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01551-2024","article-title":"Cathepsin C (dipeptidyl peptidase 1) inhibition in adults with bronchiectasis: AIRLEAF, a phase II randomised, double-blind, placebo-controlled, dose-finding study","volume":"65","author":"Chalmers","year":"2025","journal-title":"Eur Respir J"},{"key":"10.1016\/j.chest.2025.12.035_bib31","unstructured":"Institute for Clinical and Economic Review. Brensocatib for non-cystic fibrosis bronchiectasis: effectiveness and value. Institute for Clinical and Economic Review website. Accessed November 30, 2025. https:\/\/icer.org\/wp-content\/uploads\/2025\/10\/ICER_NCFB-Final-Report_For-Publication_103025.pdf"},{"issue":"3","key":"10.1016\/j.chest.2025.12.035_bib34","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1128\/CMR.00078-09","article-title":"Mechanisms of action and clinical application of macrolides as immunomodulatory medications","volume":"23","author":"Kanoh","year":"2010","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.chest.2025.12.035_bib35","doi-asserted-by":"crossref","DOI":"10.1177\/1479972318790269","article-title":"Azithromycin or erythromycin? Macrolides for non-cystic fibrosis bronchiectasis in adults: a systematic review and adjusted indirect treatment comparison","volume":"16","author":"Li","year":"2019","journal-title":"Chron Respir Dis"},{"issue":"3","key":"10.1016\/j.chest.2025.12.035_bib36","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01574-2024","article-title":"Cardiovascular benefits and safety profile of macrolide maintenance therapy in patients with bronchiectasis","volume":"65","author":"Guo","year":"2025","journal-title":"Eur Respir J"},{"issue":"12","key":"10.1016\/j.chest.2025.12.035_bib37","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/S2213-2600(14)70213-9","article-title":"The effect of long-term macrolide treatment on respiratory microbiota composition in non-cystic fibrosis bronchiectasis: an analysis from the randomised, double-blind, placebo-controlled BLESS trial","volume":"2","author":"Rogers","year":"2014","journal-title":"Lancet Respir Med"},{"issue":"12","key":"10.1016\/j.chest.2025.12.035_bib38","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1128\/AAC.39.12.2625","article-title":"Genetic basis of macrolide resistance in Mycobacterium avium isolated from patients with disseminated disease","volume":"39","author":"Nash","year":"1995","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"10.1016\/j.chest.2025.12.035_bib39","doi-asserted-by":"crossref","DOI":"10.1093\/jacamr\/dlaf047","article-title":"Macrolide resistance in Mycobacterium abscessus: current insights and future perspectives","volume":"7","author":"Nguyen","year":"2025","journal-title":"JAC Antimicrob Resist"},{"issue":"1","key":"10.1016\/j.chest.2025.12.035_bib40","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00535-2020","article-title":"Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS\/ERS\/ESCMID\/IDSA clinical practice guideline","volume":"56","author":"Daley","year":"2020","journal-title":"Eur Respir J"},{"issue":"5","key":"10.1016\/j.chest.2025.12.035_bib41","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.jiac.2017.12.008","article-title":"The association between erythromycin monotherapy for Mycobacterium avium complex lung disease and cross-resistance to clarithromycin: a retrospective case-series study","volume":"24","author":"Hosono","year":"2018","journal-title":"J Infect Chemother"},{"issue":"1","key":"10.1016\/j.chest.2025.12.035_bib42","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1164\/rccm.202307-1165OC","article-title":"Five-year outcomes among U.S. bronchiectasis and NTM research registry patients","volume":"210","author":"Aksamit","year":"2024","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"10.1016\/j.chest.2025.12.035_bib43","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1136\/thorax-2024-221825","article-title":"Use of inhaled corticosteroids in bronchiectasis: data from the European Bronchiectasis Registry (EMBARC)","volume":"80","author":"Pollock","year":"2025","journal-title":"Thorax"},{"issue":"10","key":"10.1016\/j.chest.2025.12.035_bib44","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1513\/AnnalsATS.201804-245OC","article-title":"Association between inhaled corticosteroid use and pulmonary nontuberculous mycobacterial infection","volume":"15","author":"Liu","year":"2018","journal-title":"Ann Am Thorac Soc"},{"issue":"3","key":"10.1016\/j.chest.2025.12.035_bib45","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1136\/thoraxjnl-2012-201772","article-title":"Chronic respiratory disease, inhaled corticosteroids and risk of non-tuberculous mycobacteriosis","volume":"68","author":"Andr\u00e9jak","year":"2013","journal-title":"Thorax"},{"issue":"1","key":"10.1016\/j.chest.2025.12.035_bib46","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1164\/rccm.202402-0368OC","article-title":"Association of dose of inhaled corticosteroids and frequency of adverse events","volume":"211","author":"Bloom","year":"2024","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.chest.2025.12.035_bib47","doi-asserted-by":"crossref","first-page":"1801896","DOI":"10.1183\/13993003.01896-2018","article-title":"Comparative risks of chronic inhaled corticosteroids and macrolides for bronchiectasis","volume":"54","author":"Henkle","year":"2019","journal-title":"Eur Respir J"},{"key":"10.1016\/j.chest.2025.12.035_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2020.106127","article-title":"Role of inhaled corticosteroids in reducing exacerbations in bronchiectasis patients with blood eosinophilia pooled post-hoc analysis of 2 randomized clinical trials","volume":"172","author":"Martinez-Garcia","year":"2020","journal-title":"Respir Med"},{"issue":"3","key":"10.1016\/j.chest.2025.12.035_bib49","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.chest.2023.04.029","article-title":"The U-shaped relationship between eosinophil count and bronchiectasis severity: the effect of inhaled corticosteroids","volume":"164","author":"Mart\u00ednez-Garc\u00eda","year":"2023","journal-title":"Chest"},{"issue":"6","key":"10.1016\/j.chest.2025.12.035_bib50","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00051-2017","article-title":"Pulmonary exacerbation in adults with bronchiectasis: a consensus definition for clinical research","volume":"49","author":"Hill","year":"2017","journal-title":"Eur Respir J"}],"container-title":["CHEST"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369226000103?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369226000103?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T15:26:49Z","timestamp":1781018809000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0012369226000103"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":47,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S0012369226000103"],"URL":"https:\/\/doi.org\/10.1016\/j.chest.2025.12.035","relation":{},"ISSN":["0012-3692"],"issn-type":[{"value":"0012-3692","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of Antiinflammatory Therapies for Adults With Non-Cystic Fibrosis Bronchiectasis","name":"articletitle","label":"Article Title"},{"value":"CHEST","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.chest.2025.12.035","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American College of Chest Physicians. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}